Chief Executive Officer

Dr. Grant Senner, MD, DABRM is a tested physician executive and entrepreneur with over twenty years of corporate, legal, regulatory and medical finance expertise within the life science and healthcare sectors. He brings progressive healthcare leadership experience with proven success in achieving strategic, operational and financial objectives. His diverse background includes expertise in biomedical technology and commercialization, health finance, clinical program development, medical reimbursement and population health management spanning the commercial and academic sectors.

Upon completion of his Doctorate, Dr. Senner served as Fellow and Consultant for the state of Arizona’s Medicaid agency where he focused on Centers for Medicare and Medicaid Services (CMS) reimbursement models and coordination of care for individuals with complex needs in a patient-centered model. Subsequently, he held key leadership positions within community-based medical practice and biomedical technology companies. In 2012, he joined University of Arizona Health Sciences, University of Arizona, as Director of Special Projects and Strategic Initiatives and was responsible for analysis of market opportunities and support of grant and contract development. Currently, Dr. Senner serves as founder and CEO of several companies focused on regenerative human and veterinary science, including Equus Innovations (Phoenix, AZ) which manufactures the RenoVō ® equine allograft.

An Honors graduate of the University of Arizona with a Bachelor of Science in Molecular and Cellular Biology, Dr. Senner attended the University of Arizona College of Medicine – Tucson and graduated with his Doctorate of Medicine in 2004. In 2014, his family established the Senner Endowment for Precision Health within University of Arizona Health Sciences, dedicated to support the use of genetic profiles to guide the diagnosis, prediction, treatment and prevention of disease.


Senior Director of Quality & Compliance

Ann Kolesar, MBA, is a seasoned Quality professional, with nearly 30 years experience in FDA regulated industries. She brings extensive knowledge of manufacturing and aseptic processing in pharmaceutical, medical device, biologic, and tissue bank environments, and her diverse background includes expertise in Quality Operations and International Regulatory Compliance (US, EU, CAN).

After beginning her career in the production of aseptic pharmaceuticals, Ann has held numerous leadership positions to include oversight of Quality Assurance, Quality Control, Quality Engineering, Quality Compliance, and Regulatory Affairs. Experience includes direct oversight of Manufacturing and/or Quality (US and OUS) for a variety of dosage forms to include human parenteral, oral solid, and topical pharmaceuticals, Class III medical devices including combination products, HCT/Ps and veterinary products, in traditional manufacturing, contract manufacturing and virtual environments. Development and management of Quality Systems includes 21 CFR parts 210, 211, 820, 600, 11, 1271; EU MDD 93/42/EEC (2007/47/EC); Ca. C.R.C, c. 870 and SOR/2003-196; AATB; and ISO 13485, 14971 and 9001. Regulatory and Grant submissions include DMF, (Ca) PLA and CTA, IND, ISO 13485 and SBIR.

A proven, cross-functional leader, Ann has consistently met the challenges facing corporate, small business, and start-up companies, utilizing creative approaches and risk-based strategies to achieve compliance objectives while actively managing budget impact. Currently, she serves as the Sr. Director Quality & Compliance for Equus Innovations (Phoenix, Arizona), the manufacturer of the RenoVō® equine allograft.

Ann holds a Bachelor of Science in Biology from Arizona State University and a Master of Business Administration from the University of Phoenix.


Chief Operating and Scientific Officer

Mr. Beaudry is an executive and entrepreneur with more than twenty-one years of bio pharmaceutical and scientific research experience and brings proven success in the development and commercialization of novel biological products. His diverse background includes expertise in cellular biology, biomedical technology, regulatory compliance, quality systems, business operations, research and development, and scientific research spanning the commercial and academic sectors.His professional experience includes directing and managing biopharmaceutical research facilities as well as conducting new product development and research investigations.

Mr. Beaudry is co-founder of Equus Innovations (Phoenix, AZ) where he serves as Chief Operating and Scientific Officer and Member, Board of Managers.In this capacity, he is responsible for overall research and development of amniotic tissue allografts and technologies including RenoVō®, a next generation equine biologic. Prior to founding Equus Innovations, Mr. Beaudry served as Chief Scientific Officer at Amnio Technology where he was instrumental in developing and bringing to market the company’s human amniotic tissue product offerings. Additionally, he is listed asan inventor on 18 issued and patents pending, has co-authored 29 published scientific articles and 2 book chapters, and has held numerous research and operational appointments. Mr. Beaudry earned a Master of Business Administration from the University of Phoenix, a Bachelor of Science in Medical Biology from the University of Quebec, is a certified Tissue Bank Specialist by the American Association of Tissue Banks, and is a Diplomat of the American Board of Regenerative Medicine.

Bio_Photo_Jaehyun Kim

Jaehyun Kim, Ph.D.

Director of Research and Operations

Jaehyun Kim, Ph.D. is a Bioengineer with over 25 years of expertise in tissue engineering and regenerative medicine with a focus on wound healing and orthopedic research. Dr. Kim joined Equus Innovations as Director of Research and Operations in 2021 and leads development of novel products, innovations and methods of use for placental tissue allografts. He also provides oversight of manufacturing operations.

Prior to his work at Equus Innovations, Dr. Kim held R&D leadership roles for the scientific research and development of novel products and technologies derived from human placental tissues and technical support for manufacturing and premarket approval of 351 HCT/P.

During his academic years, Dr. Kim served as a Research Fellow at the Wake Forest Institute for Regenerative Medicine (WFIRM) for 6 years, a leading institution for developing replacement tissues and organs. In this role, Dr. Kim led interdisciplinary teams and directed multiple basic and translational research projects, including development of novel epidermal and dermal substitutes via in situ 3D bioprinting technology combined with stem cell therapy utilizing immunomodulatory properties. Dr. Kim also led projects targeting treatment of ischemic injuries where he discovered that the use of endogenous pharmacologic agent and its derivatives achieved induction of metabolic downregulation resulting in enhanced cell and tissue survival in necrotic tissues. Based on this finding, he formulated drug-eluting hydrogels for sustained release of cyto-protective agent in a translational effort. Through 3 years of post-doctoral research in Bioengineering at the University of Pennsylvania, Dr. Kim established a novel sol-gel technology for controlled delivery of osteogenic factors and unveiled the mechanism of cell-biomaterial interactions for osteogenesis. In recognition of his outstanding research, Dr. Kim has received many prestigious awards.

Dr. Kim holds a B.S. in Biology and M.S. & Ph.D. in Biomedical Engineering from University of Iowa with a focus on Biomaterials and Biomechanics. In addition, Dr. Kim is a Certified Tissue Banking Specialist (CTBS) by the American Association of Tissue Banks.


Veterinary Director


Contract Manager